Ayse Yesbek Kaymaz

Dr. Ayse Yesbek Kaymaz

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 2022 in Muscle & Nerve
Verified
Journal Article
Closed access
AKAyse Yesbek Kaymaz
Ayse Yesbek Kaymaz
SBSevgi Kostel Bal
Sevgi Kostel Bal
GAGamze Bora Akoğlu
Gamze Bora Akoğlu
BTBeril Talim
Beril Talim
AOAlev Ozon
Alev Ozon
HYHayat Erdem Yurter
Hayat Erdem Yurter

25 February 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
AKAyse Yesbek Kaymaz
Ayse Yesbek Kaymaz
GAGamze Bora Akoğlu
Gamze Bora Akoğlu
HYHayat Erdem Yurter
Hayat Erdem Yurter
CGChristopher Grunseich
Christopher Grunseich
Advances in technology have provided a better understanding of the genetic basis of neurodegenerative disorders and their underlying molecular pathophysiology. However, treating these disorders with conventional strategies is a major challenge. The approval of gene-targeted therapy for spinal muscular atrophy (SMA) has laid the foundation for developing therapies for other neurodegenerative disorders. Highly personalized gene therapy trials have been reported. As intensive research and efforts to advance gene-targeted therapies continue, this review provides an overview of viral and non-viral vectors and delivery methods, as well as treatment strategies, including gene addition, replacement, editing, silencing, and splice modulation. Gene-targeted approaches and clinical trials for SMA and amyotrophic lateral sclerosis (ALS) have demonstrated success, and additional studies are in progress. The design of efficient clinical trials which facilitate successful translation into clinical practice is of critical importance. Key considerations include the selection of appropriate disease models, understanding the natural history of the disease, and establishing well-defined outcome measures to assess prognosis of the disease and therapeutic efficacy. Finally, the precision of CRISPR-gene editing may facilitate the development of new therapies.

1 April 2026 in Genes
Verified
Journal Article
Open access
PDF file
AKAyse Yesbek Kaymaz
Ayse Yesbek Kaymaz
GAGamze Bora Akoğlu
Gamze Bora Akoğlu
HYHayat Erdem Yurter
Hayat Erdem Yurter
CGChristopher Grunseich
Christopher Grunseich
Advances in technology have provided a better understanding of the genetic basis of neurodegenerative disorders and their underlying molecular pathophysiology. However, treating these disorders with conventional strategies is a major challenge. The approval of gene targeted therapy for spinal muscular atrophy (SMA) has laid the foundation for developing highly personalized therapies for other neurodegenerative disorders. As intensive research and efforts to advance gene targeted therapies continue, this review provides an overview of viral and non-viral vectors and delivery methods, as well as treatment strategies, including gene addition, replacement, editing, silencing, and splice modulation. Gene targeted approaches and clinical trials for SMA and amyotrophic lateral sclerosis (ALS) have demonstrated success, and additional studies are in progress. The design of efficient clinical trials which facilitate successful translation into clinical practice is of critical importance. Key considerations include the selection of appropriate disease models, understanding the natural history of the disease, and establishing well-defined outcome measures to assess prognosis of the disease and therapeutic efficacy. Finally, the precision of CRISPR-based gene editing offers the potential for one-time corrective therapies for monogenic disorders like SMA and SOD1-ALS.